The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead
Open accessAbstract
Non-Hodgkin lymphoma is the fourth most common malignancy in children, has an even higher incidence in adolescents, and is primarily represented by only a few histologic subtypes. Dramatic progress has been achieved, with survival rates exceeding 80%, in large part because of a better understanding of the biology of the different subtypes and national and international collaborations. Most patients with Burkitt lymphoma and diffuse large B-cell lymphoma are cured with short intensive pulse chemotherapy containing cyclophosphamide, cytarabine, and high-dose methotrexate. The benefit of the addition of rituximab has not been established except in the case of primary mediastinal B-cell lymphoma. Lymphoblastic lymphoma is treated with intensive, semi-continuous, longer leukemia-derived protocols. Relapses in B-cell and lymphoblastic lymphomas are rare and infrequently curable, even with intensive approaches. Event-free survival rates of approximately 75% have been achieved in anaplastic large-cell lymphomas with various regimens that generally include a short intensive B-like regimen. Immunity seems to play an important role in prognosis and needs further exploration to determine its therapeutic application. ALK inhibitor therapeutic approaches are currently under investigation. For all pediatric lymphomas, the intensity of induction/consolidation therapy correlates with acute toxicities, but because of low cumulative doses of anthracyclines and alkylating agents, minimal or no long-term toxicity is expected. Challenges that remain include defining the value of prognostic factors, such as early response on positron emission tomography/computed tomography and minimal disseminated and residual disease, using new biologic technologies to improve risk stratification, and developing innovative therapies, both in the first-line setting and for relapse.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995
US Department of Health and Human Services; National Cancer Institute (1999) · PsycEXTRA Dataset · doi:10.1037/e407432005-001 · Cited by 1,947
Pro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., Matous, J., Ramchandren, R., Fanale, M., Connors, J. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0402 · Cited by 997
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics
Schmitz, R., Young, R. M., Ceribelli, M., Jhavar, S., Xiao, W., Zhang, M., Wright, G., Shaffer, A. L., Hodson, D. J., Buras, E., et al. (2012) · Nature · doi:10.1038/nature11378 · Cited by 924
Mossé, Y. P., Lim, M. S., Voss, S. D., Wilner, K., Ruffner, K., Laliberte, J., Rolland, D., Balis, F. M., Maris, J. M., Weigel, B. J., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70095-0 · Cited by 712
The genetic landscape of mutations in Burkitt lymphoma
Love, C., Sun, Z., Jima, D., Li, G., Zhang, J., Miles, R., Richards, K. L., Dunphy, C. H., Choi, W. W. L., Srivastava, G., et al. (2012) · Nature Genetics · doi:10.1038/ng.2468 · Cited by 597
Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma
Dunleavy, K., Pittaluga, S., Maeda, L. S., Advani, R., Chen, C. C., Hessler, J., Steinberg, S. M., Grant, C., Wright, G., Varma, G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214561 · Cited by 569
Patte, C. (2001) · Blood · doi:10.1182/blood.v97.11.3370 · Cited by 538
Self-citationWimmer, K., Kratz, C. P., Vasen, H. F. A., Caron, O., Colas, C., Entz-Werle, N., Gerdes, A.-M., Goldberg, Y., Ilencikova, D., Muleris, M., et al. (2014) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2014-102284 · Cited by 485
Self-citationthe ICGC MMML-Seq Project (2012) · Nature Genetics · doi:10.1038/ng.2469 · Cited by 440
Patte, C., Auperin, A., Gerrard, M., Michon, J., Pinkerton, R., Sposto, R., Weston, C., Raphael, M., Perkins, S. L., McCarthy, K., et al. (2007) · Blood · doi:10.1182/blood-2006-07-036673 · Cited by 430
Self-citationDuval, M. (2002) · Blood · doi:10.1182/blood.v99.8.2734 · Cited by 408
Cairo, M. S., Gerrard, M., Sposto, R., Auperin, A., Pinkerton, C. R., Michon, J., Weston, C., Perkins, S. L., Raphael, M., McCarthy, K., et al. (2007) · Blood · doi:10.1182/blood-2006-07-036665 · Cited by 363
Self-citationWoessmann, W. (2004) · Blood · doi:10.1182/blood-2004-03-0973 · Cited by 359
Self-citationAmylon, M., Shuster, J., Pullen, J., Berard, C., Link, M., Wharam, M., Katz, J., Yu, A., Laver, J., Ravindranath, Y., et al. (1999) · Leukemia · doi:10.1038/sj.leu.2401310 · Cited by 347
Burkhardt, B., Zimmermann, M., Oschlies, I., Niggli, F., Mann, G., Parwaresch, R., Riehm, H., Schrappe, M., Reiter, A., & for the BFM Group (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05735.x · Cited by 334
Self-citationSynergy between PI3K Signaling and MYC in Burkitt Lymphomagenesis
Sander, S., Calado, D. P., Srinivasan, L., Köchert, K., Zhang, B., Rosolowski, M., Rodig, S. J., Holzmann, K., Stilgenbauer, S., Siebert, R., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.012 · Cited by 300
Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase–Positive Lymphoma Patients
Gambacorti Passerini, C., Farina, F., Stasia, A., Redaelli, S., Ceccon, M., Mologni, L., Messa, C., Guerra, L., Giudici, G., Sala, E., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt378 · Cited by 279
Self-citationYounes, A., Thieblemont, C., Morschhauser, F., Flinn, I., Friedberg, J. W., Amorim, S., Hivert, B., Westin, J., Vermeulen, J., Bandyopadhyay, N., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70311-0 · Cited by 254
Gerrard, M., Cairo, M. S., Weston, C., Auperin, A., Pinkerton, R., Lambilliote, A., Sposto, R., McCarthy, K., Lacombe, M. T., Perkins, S. L., et al. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07144.x · Cited by 199
Self-citationMeinhardt, A., Burkhardt, B., Zimmermann, M., Borkhardt, A., Kontny, U., Klingebiel, T., Berthold, F., Janka-Schaub, G., Klein, C., Kabickova, E., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.6791 · Cited by 186
Self-citationAsselin, B. L., Devidas, M., Wang, C., Pullen, J., Borowitz, M. J., Hutchison, R., Lipshultz, S. E., & Camitta, B. M. (2011) · Blood · doi:10.1182/blood-2010-06-292615 · Cited by 172
Anderson, J. R., Jenkin, R. D., Wilson, J. F., Kjeldsberg, C. R., Sposto, R., Chilcote, R. R., Coccia, P. F., Exelby, P. R., Siegel, S., & Meadows, A. T. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.6.1024 · Cited by 170
Griffin, T. C., Weitzman, S., Weinstein, H., Chang, M., Cairo, M., Hutchison, R., Shiramizu, B., Wiley, J., Woods, D., Barnich, M., et al. (2009) · Pediatric Blood & Cancer · doi:10.1002/pbc.21753 · Cited by 169
Self-citationTanaka, H., Matsushima, H., Mizumoto, N., & Takashima, A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1101 · Cited by 163
A Mendelian predisposition to B-cell lymphoma caused by IL-10R deficiency
Neven, B., Mamessier, É., Bruneau, J., Kaltenbach, S., Kotlarz, D., Suárez, F., Masliah‐Planchon, J., Billot, K., Canioni, D., Frange, P., et al. (2013) · Blood · doi:10.1182/blood-2013-06-508267 · Cited by 144
Tanaka, H., Matsushima, H., Nishibu, A., Clausen, B. E., & Takashima, A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1106 · Cited by 134
Poirel, H. A., Cairo, M. S., Heerema, N. A., Swansbury, J. G., Auperin, A., Launay, E., Sanger, W. G., Talley, P., Perkins, S. L., Raphaël, M., et al. (2008) · Leukemia · doi:10.1038/leu.2008.312 · Cited by 134
Self-citationAit‐Tahar, K., Damm‐Welk, C., Burkhardt, B., Zimmermann, M., Klapper, W., Reiter, A., Pulford, K. A. F., & Woessmann, W. (2010) · Blood · doi:10.1182/blood-2009-11-251892 · Cited by 132
Self-citationCallens, C., Baleydier, F., Lengliné, É., Abdelali, R. B., Petit, A., Villarèse, P., Cieślak, A., Minard‐Colin, V., Rullier, A., Moreau, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.7661 · Cited by 128
Self-citationBonn, B. R., Rohde, M., Zimmermann, M., Krieger, D., Oschlies, I., Niggli, F. K., Wróbel, G., Attarbaschi, A., Escherich, G., Klapper, W., et al. (2013) · Blood · doi:10.1182/blood-2012-12-474148 · Cited by 126
Self-citationMussolin, L., Pillon, M., dʼAmore, E. S. G., Santoro, N., Lombardi, A., Fagioli, F., Zanesco, L., & Rosolen, A. (2005) · Leukemia · doi:10.1038/sj.leu.2403888 · Cited by 103
Self-citationRecent advances in the understanding and management of diffuse large B‐cell lymphoma in children
Reiter, A., & Klapper, W. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.06988.x · Cited by 98
Self-citationDunsmore, K. P., Devidas, M., Linda, S. B., Borowitz, M. J., Winick, N. J., Hunger, S. P., Carroll, W. L., & Camitta, B. M. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.8724 · Cited by 94
Anaplastic large cell lymphoma treated with a leukemia‐like therapy
Rosolen, A., Pillon, M., Garaventa, A., Burnelli, R., dʼAmore, E. S. G., Giuliano, M. G., Comis, M., Cesaro, S., Tettoni, K., Moleti, M. L., et al. (2005) · Cancer · doi:10.1002/cncr.21438 · Cited by 86
Self-citationTermuhlen, A. M., Smith, L. M., Perkins, S. L., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12460 · Cited by 85
Self-citationAlexander, S. W., Kraveka, J. M., Weitzman, S. S., Lowe, E. J., Smith, L. M., Lynch, J. C., Chang, M. N., Kinney, M. C., Perkins, S. L., Laver, J. H., et al. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25187 · Cited by 79
Self-citationAbromowitch, M., Sposto, R., Perkins, S. L., Zwick, D. L., Siegel, S. E., Finlay, J. L., & Cairo, M. S. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07320.x · Cited by 60
Self-citationGreenough, A., & Davé, S. S. (2014) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000059 · Cited by 23
Cited by
2016 US lymphoid malignancy statistics by World Health Organization subtypes
Teras, L. R., DeSantis, C. E., Cerhan, J. R., Morton, L. M., Jemal, A., & Flowers, C. R. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21357 · Cited by 1,125
“Less is known about risk factors for pediatric diffuse large B-cell lymphomas, but insights into the biology of these cancers suggest that they are more molecularly heterogeneous than adult diffuse large B-cell lymphomas.(45) Although Burkitt lymphoma is relatively rare in the United States, it is one of the most comm…”
Background
Metadata
- Authors
- Minard-Colin, V., Brugières, L., Reiter, A., Cairo, M. S., Gross, T. G., Woessmann, W., Burkhardt, B., Sandlund, J. T., Williams, D., Pillon, M., Horibe, K., Auperin, A., Le Deley, M.-C., Zimmerman, M., Perkins, S. L., Raphael, M., Lamant, L., Klapper, W., Mussolin, L., Poirel, H. A., Macintyre, E., Damm-Welk, C., Rosolen, A., & Patte, C.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-09-20
- Volume
- 33
- Issue
- 27
- Pages
- 2963-2974
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2162244898
- Cited by
- 290
- References
- 39
- FWCI
- 14.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.